Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitrectomy +/- Triamcinolone or Bevacizumab for Diffuse Diabetic Macular Edema
NCT00600301Phase 3Withdrawn
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Jan 2008
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of triamcinolone acetonide, bevacizumab in diabetic macular edema (DME), sponsored by Asociación para Evitar la Ceguera en México. Planned start Jan 2008; status: withdrawn.
02
Drugs
triamcinolone acetonidebevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00600301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600301.